Sentinel lymph node biopsy in melanoma: Facts and controversies

Clinics in Dermatology

Volumn 28, Issue 3, 2010, Pages 319-323

  Baldwin, Brooke T ^a   Cherpelis, Basil S ^a   Sondak, Vernon ^b   Fenske, Neil Alan ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER SURVIVAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; IMMUNOHISTOCHEMISTRY; MELANOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENTINEL LYMPH NODE BIOPSY; TREATMENT INDICATION; MORTALITY; MULTICENTER STUDY (TOPIC); PATHOLOGY; PRACTICE GUIDELINE; PROCEDURES; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN TUMOR; SURVIVAL;

HUMANS; MELANOMA; MULTICENTER STUDIES AS TOPIC; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; SURVIVAL ANALYSIS;

EID: 77953602177     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2009.06.016     Document Type: Article

References (34)

1. Perrot R.E., Glass L.F., Reintgen D.S., et al. Reassessing the role of lymphatic mapping and sentinel lymphadenectomy in the management of cutaneous malignant melanoma. J Am Acad Dermatol 2003, 49:567-588.
2. Morton D.L., Wen D.R., Wong J.H., et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992, 127:392-399.
3. Reintgen D., Cruse C.W., Wells K., et al. The orderly progression of melanoma and nodal metastases. Ann Surg 1994, 220:759-767.
4. Messina J.L., Glass L.F., Cruse C.W., Berman C., Ku N.K., Reintgen D.S. Pathologic examination of the sentinel lymph node in malignant melanoma. Am J Surg Pathol 1999, 23:686-690.
5. Gershenwald J.E., Colome M.I., Lee J.E., et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol 1998, 16:2253-2260.
6. Morton D.L., Thompson J.F., Essner R., et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. Ann Surg 1999, 230:453-463.
7. Li W., Stall A., Shivers S.C., et al. Clinical relevance of molecular staging for melanoma: comparison of RT-PCR and immunohistochemistry staining in sentinel lymph nodes of patients with melanoma. Ann Surg 2000, 231:795-803.
8. Shivers S.C., Wang X., Li W., et al. Molecular staging of malignant melanoma: correlation with clinical outcome. JAMA 1998, 280:1410-1415.
9. Scoggins C.R., Ross M.I., Reintgen D.S., et al. Prospective multi-institutional study of reverse transcriptase polymerase chain reaction for molecular staging of melanoma. J Clin Oncol 2006, 24:2849-2856.
10. Morton D.L., Thompson J.F., Cochran A.J., et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006, 355:1307-1317.
11. Morton D.L., Cochran A.J., Thompson J.F. Author's response to a letter to the editor regarding: Sentinel node biopsy for early-stage melanoma. Ann Surg 2007, 245:828-829.
12. McKinnon J.G., Yu X.Q., McCarthy W.H., Thompson J.F. Prognosis for patients with thin cutaneous melanoma: long term survival data from New South Wales Central Cancer Registry and the Sydney Melanoma Unit. Cancer 2003, 98:1223-1231.
13. Kalady M.F., White R.R., Johnson J.L., Tyler D.S., Seigler H.F. Thin melanomas: predictive lethal characteristics from a 30 year clinical experience. Ann Surg 2003, 238:528-535.
14. Wright B.E., Scheri R.P., Ye X., et al. Importance of sentinel lymph node biopsy in patients with thin melanoma. Arch Surg 2008, 143:892-899. discussion 899-900.
15. Zitelli J.A. Sentinel lymph node biopsy: an alternate view. Dermatol Surg 2008, 34:544-549.
16. Starz H., Siedlecki K., Balda B.R. Sentinel lymphadenectomy and S-classification: a successful strategy for better prediction and improvement of outcome in melanoma. Ann Surg Oncol 2004, 11:162S-168S.
17. Carlson G.W., Murray D.R., Lyles R.H., et al. The amount of metastatic melanoma in a sentinel lymph node: does it have prognostic significance?. Ann Surg Oncol 2003, 10:575-581.
18. Spanknebel K., Coit D.G., Bieligk S.C., et al. Characterisation of micrometastatic disease in melanoma sentinel lymph nodes by enhanced pathology: recommendations for standardizing pathologic analysis. Am J Surg Pathol 2005, 29:305-317.
19. Yu L.L., Flotte T.J., Tanabe K.K., et al. Detection of microscopic melanoma metastases in sentinel lymph nodes. Cancer 1999, 86:617-627.
20. Li L.X., Scolyer R.A., Ka V.S., et al. Pathologic review of negative sentinel lymph nodes in melanoma patients with regional recurrence: a clinicopathologic study of 1152 patients undergoing sentinel lymph node biopsy. Am J Pathol 2003, 27:1197-1202.
21. Thompson J.F. The value of sentinel lymph node biopsy in patients with primary cutaneous melanoma. Dermatol Surg 2008, 34:550-555.
22. Gershenwald J.E., Ross M.I. Is sentinel node biopsy superior to nodal observation in melanoma?. Nat Clin Pract Oncol 2007, 4:278-279.
23. Gershenwald J.E., Thompson W., Mansfield P.F., et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999, 17:976-983.
24. McMasters K.M., Sondack V.K., Lotze M.T., et al. Recent advances in melanoma staging and therapy. Ann Surg Oncol 1999, 6:467-475.
25. Balch C.M., Buzaid A.C., Atkins M.B., et al. A new American joint committee on cancer staging system for cutaneous melanoma. Cancer 2000, 88:1484-1491.
26. Balch C.M., Soong S.J., Gershenwald J.E., et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001, 19:3622-3634.
27. Ferrone C.R., Panageas K.S., Busam K., et al. Multivariate prognostic model for patients with thick cutaneous melanoma: importance of sentinel lymph node status. Ann Surg Oncol 2002, 9:637-645.
28. Zettersten E., Shaikh L., Ramirez R., et al. Prognostic factors in primary cutaneous melanoma. Surg Clin North Am 2003, 83:61-75.
29. Kirkwood J.M., Manola J., Ibrahim J., Sondak V., Ernstoff M.S., Rao U. A pooled analysis of Eastern Cooperative Oncology Group and Intergroup trials of adjuvant high dose interferon for melanoma. Clin Cancer Res 2004, 19:1670-1677.
30. Kilbridge K.L., Weeks J.C., Sober A.J., et al. Patient preferences for adjuvant interferon alfa-2b treatment. J Clin Oncol 2001, 19:812-823.
31. Gray R.J., Pockai B.A., Kirkwood J.M. An update on adjuvant interferon for melanoma. Cancer Control 2002, 9:16-21.
32. Puelo C.A., Messina J.L., Riker A.L., et al. Sentinel node biopsy for thin melanomas. Which patients should be considered. Cancer Control 2005, 12:230-235.
33. Wallace A.M., Hoh C.K., Ellner S.J., et al. Lymphoseek: a molecular imaging agent for melanoma sentinel node mapping. Ann Surg Oncol 2007, 14:913-921.
34. Sondak V.K., Messina J.L. Current status of biomarkers for melanoma metastases. IDrugs 2006, 9:627-631.